
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is facing a challenging year in terms of sales growth due to the effects of the COVID-19 pandemic on the medical industry as well as ongoing regulatory hurdles. However, the company's well-managed expenses and an optimistic outlook for their natural healing-focused product portfolio present long-term potential for TELA Bio's financial success. While there may be near-term challenges, the company's commitment to prioritizing the preservation and restoration of the patient's anatomy sets TELA Bio apart in the competitive market of synthetic mesh manufacturers.
Bears say
TELA Bio is facing significant challenges as it continues to undergo a strategic overhaul and make changes to its sales team and commercial strategy. This has led to a lowered guidance for revenue growth, causing concern about the company's ability to execute and maintain stability in its sales force. There are also concerns about potential disruptions from these changes and a potential delay in reaching profitability. Furthermore, TELA Bio is heavily reliant on the success of its limited product portfolio, which may be impacted by reimbursement rates and competition in the market. Overall, these factors contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares